Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐ versus ‐host disease development in humanized mice treated with post‐transplant cyclophosphamide
Immunology & Cell Biology · 2023
DOI: 10.1111/imcb.12652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology & Cell Biology, 2023. Verfasst von Chloe Sligar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Council NSW.
Abstract (Originalsprache)
Graft‐ versus ‐host disease (GVHD) is a life‐threatening complication following donor hematopoietic stem cell transplantation, where donor T cells damage host tissues. This study investigated the effect of tocilizumab (TOC) combined with post‐transplant cyclophosphamide (PTCy) on immune cell engraftment and GVHD development in a humanized mouse model. NOD‐ scid ‐IL2Rγ null (NSG) mice were injected intraperitoneally with 2 × 10 7 human (h) peripheral blood mononuclear cells and cyclophosphamide (33 mg kg −1 ) or saline on days 3 and 4, then TOC or control antibody (0.5 mg mouse −1 ) twice weekly for 28 days. Mice were monitored for clinical signs of GVHD for either 28 or 70 days. Spleens and livers were assessed for human leukocyte subsets, and serum cytokines and tissue histology were analyzed. In the short‐term model (day 28), liver and lung damage were reduced in PTCy + TOC compared with control mice. All groups showed similar splenic hCD45 + leukocyte engraftment (55–60%); however, PTCy + TOC mice demonstrated significantly increased (1.5–2‐fold) splenic regulatory T cells. Serum human interferon gamma was significantly reduced in PTCy + TOC compared with control mice. Long‐term (day 70), prolonged survival was similar in PTCy + TOC (median survival time, > 70 days) and PTCy mice (median survival time, 56 days). GVHD onset was significantly delayed in PTCy + TOC, compared with TOC or control mice. Notably, natural killer cells were reduced (77.5%) in TOC and PTCy + TOC mice. Overall, combining PTCy with TOC increases regulatory T cells and reduces clinical signs of early GVHD, but does not improve long‐term survival compared with PTCy alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.
- Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, Australia.
- The Centre for Kidney Research, The Children's Hospital at Westmead, NSW, Westmead, Australia.
ORCID-Profile: Chloe Sligar, Peter Cuthbertson, Nicole A Miles, Sam R Adhikary, Amal Elhage, Geoff Zhang, Stephen I Alexander, Ronald Sluyter
Förderung
- Cancer Council NSW
Zitieren
APA
Sligar, C., Cuthbertson, P., Miles, N. A., Adhikary, S. R., Elhage, A., Zhang, G., Alexander, S. I., Sluyter, R., & Watson, D. (2023). Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐ versus ‐host disease development in humanized mice treated with post‐transplant cyclophosphamide. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12652
Vancouver
Sligar C, Cuthbertson P, Miles NA, Adhikary SR, Elhage A, Zhang G, et al. Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐ versus ‐host disease development in humanized mice treated with post‐transplant cyclophosphamide. Immunology & Cell Biology. 2023. doi:10.1111/imcb.12652
BibTeX
@article{Sligar2023,
author = {Sligar, Chloe and Cuthbertson, Peter and Miles, Nicole A and Adhikary, Sam R and Elhage, Amal and Zhang, Geoff and Alexander, Stephen I and Sluyter, Ronald and Watson, Debbie},
title = {Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐ versus ‐host disease development in humanized mice treated with post‐transplant cyclophosphamide},
journal = {Immunology & Cell Biology},
year = {2023},
doi = {10.1111/imcb.12652}
}
EUVIMED